Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in achieving adequate control of motor complications in patients with advanced Parkinson’s Disease (APD). Background:…Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…Systematic Review and Network Meta-Analysis of COMT and MAO-B Inhibitors in Parkinson’s Patients with Motor Fluctuations
Objective: This study compared the effects of catechol-O-methyl transferase (COMT) inhibitors and monoamine oxidase‑B (MAO-B) inhibitors on mean change from baseline to end-of-study in OFF-time…OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?
Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…The effect of co-administration of opicapone on the pharmacokinetics of levodopa
Objective: Few studies have examined levodopa (LD) pharmacokinetics in combination with opicapone (OPC) in Japanese patients with Parkinson's disease (PD). Therefore, we investigated changes in…Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center
Objective: To assess effectiveness and safety profile of Opicapone in our cohort of patients with Parkinson’s disease (PD) who received this treatment. Background: Opicapone is…Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies
Objective: To assess the effects of opicapone (OPC) 50 mg adjunct to carbidopa/levodopa (CD/LD) on catechol-O-methyltransferase (COMT) activity by participants’ baseline characteristics using pooled data…Safety of opicapone after 5 years of post-marketing experience worldwide
Objective: To review the safety data of opicapone (OPC) after five years of marketing experience worldwide Background: OPC is a once-daily catechol-O-methyltransferase (COMT) inhibitor proven…Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg on the pharmacokinetics (PK) of levodopa (LD) in different LD/carbidopa (LD/CD)…Status Update of EPSILON: a Phase III, Randomised, Placebo-Controlled Study of Opicapone in Early Parkinson’s Disease
Objective: This study aims to explore the potential of once-daily opicapone (OPC) 50 mg to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi)…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »